Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 24;18(2):242.
doi: 10.3390/ijms18020242.

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease

Cristoforo Comi  1 , Marco Ferrari  2 , Franca Marino  3 , Luca Magistrelli  4 , Roberto Cantello  5 , Giulio Riboldazzi  6 , Maria Laura Ester Bianchi  7 , Giorgio Bono  8 , Marco Cosentino  9
Affiliations

Polymorphisms of Dopamine Receptor Genes and Risk of L-Dopa-Induced Dyskinesia in Parkinson's Disease

Cristoforo Comi et al. Int J Mol Sci. .

Abstract

L-dopa-induced dyskinesia (LID) is a frequent motor complication of Parkinson's disease (PD), associated with a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and LID, the results of which have not been confirmed. The present study is aimed to determine whether genetic differences of DR are associated with LID in a small but well-characterized cohort of PD patients. To this end we enrolled 100 PD subjects, 50 with and 50 without LID, matched for age, gender, disease duration and dopaminergic medication in a case-control study. We conducted polymerase chain reaction for single nucleotide polymorphisms (SNP) in both D1-like (DRD1A48G; DRD1C62T and DRD5T798C) and D2-like DR (DRD2G2137A, DRD2C957T, DRD3G25A, DRD3G712C, DRD4C616G and DRD4nR VNTR 48bp) analyzed genomic DNA. Our results showed that PD patients carrying allele A at DRD3G3127A had an increased risk of LID (OR 4.9; 95% CI 1.7-13.9; p = 0.004). The present findings may provide valuable information for personalizing pharmacological therapy in PD patients.

Keywords: Parkinson’s disease; SNPs; disease progression; motor complications; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Correlations between rs6280 (DRD G25A) and time to dyskinesia. * = p < 0.005.
See this image and copyright information in PMC

References

    1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann. Neurol. 2000;47:S2–S11. - PubMed
    1. Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: Clinical manifestations. Mov. Disord. 2005;20:S11–S16. doi: 10.1002/mds.20458. - DOI - PubMed
    1. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Mov. Disord. 2005;20:919–931. doi: 10.1002/mds.20612. - DOI - PubMed
    1. Fabbrini G., Brotchie J.M., Grandas F., Nomoto M., Goetz G.C. Levodopa-induced dyskinesias. Mov. Disord. 2007;22:1379–1389. doi: 10.1002/mds.21475. - DOI - PubMed
    1. Calabresi P., Di Filippo M., Ghiglieri V., Picconi B. Molecular mechanisms underlying levodopa-induced dyskinesia. Mov. Disord. 2008;23:S570–S579. doi: 10.1002/mds.22019. - DOI - PubMed

LinkOut - more resources